A popular class of weight loss drugs may offer more lasting success than assumed, new data from Epic Research suggests. The study of medical records found that a slight majority of people who took GLP-1 drugs like semaglutide either maintained or improved their weight loss in the year after they stopped using the…
Another year, another round of inscrutable price increases for many prescription drugs. Over 700 medicines are seeing their list prices shoot up this January, according to an analysis by the organization 46brooklyn Research. The average price increase is slightly below the trend of recent years, but includes popular…
A popular class of weight loss and diabetes drugs looks to be safer than feared, at least so far. This week, the Food and Drug Administration announced it hasn’t found compelling evidence that Wegovy, Ozempic, and other GLP-1 drugs can cause suicidal thoughts or behaviors—a concern that first emerged last year. The…
Wegovy and similar weight loss drugs may cause more side effects than currently recognized. The Food and Drug Administration is now looking into whether these new generation obesity drugs can trigger hair loss, suicide ideation, and food aspiration, based on adverse event reports linked to their use. These reports are…
Few prescription drugs have entered the public consciousness as abruptly as Ozempic and Wegovy have in recent years. Novo Nordisk’s brand-name medications have become as synonymous with weight loss as Viagra and Cialis are with erectile dysfunction. But while 2023 has made it clear that these and similar drugs really…
New research shows that tirzepatide, the latest FDA-approved obesity drug, really can help people lose substantial amounts of weight—but only if they continue taking it. The study found that people who stopped taking tirzepatide after 36 weeks regained much of their lost weight within a year, while those who continued…
New research seems to show the potential of a CRISPR-based gene therapy meant to neuter certain forms of cardiovascular disease. In the world’s first human trial of the therapy, people given the highest doses experienced significant and long-lasting reductions in their low-density lipoprotein cholesterol (LDL-C). The…
There’s officially a new and fierce competitor for Novo Nordisk’s Wegovy (semaglutide) when it comes to weight loss. On Wednesday, the Food and Drug Administration approved the drug tirzepatide, developed by Eli Lilly, as a treatment for obesity. The weekly injectable drug will be sold under the brand name Zepbound.
Health officials in Austria are the latest to warn the public to stay away from sketchy sources of semaglutide, the active ingredient in popular weight loss drugs Wegovy and Ozempic, following recent reports of severe adverse effects linked to counterfeit products. Residents have reportedly been hospitalized with…
New research suggests that Eli Lilly’s tirzepatide can boost existing efforts to lose weight. The company’s latest clinical trial found that people who dropped at least 5% of their weight before taking the drug went on to lose substantially more weight than those who took a placebo. Those in the treatment group…
